关于HER-2阳性乳腺癌新辅助治疗疗效预测指标的研究进展
Research Progress on Prognostic Indicators of Neoadjuvant Therapy for HER-2 Positive Breast Cancer
DOI: 10.12677/ACM.2024.143712, PDF,   
作者: 张立雪, 冯 月：新疆医科大学第三临床医学院，新疆 乌鲁木齐；欧江华*：新疆医科大学附属肿瘤医院乳腺外科(二病区)，新疆 乌鲁木齐
关键词: HER-2阳性乳腺癌；新辅助治疗；预后；预测指标；pCR；HER-2 Positive Breast Cancer； Neoadjuvant Therapy； Prognosis； Predictors； pCR
摘要: 人表皮生长因子受体-2 (HER-2)阳性乳腺癌是一种预后较差的特殊类型乳腺癌。新辅助化疗联合靶向治疗，即新辅助治疗已经成为此类乳腺癌综合治疗中的重要组成部分。病理完全缓解(pCR)已被认为是HER-2阳性乳腺癌独立预后预测指标。在新辅助治疗过程中，一些患者会对治疗药物产生耐药，从而影响预后。寻找合适的预后预测指标，及时更换最优化治疗方案，对HER-2阳性乳腺癌患者的预后有极大改善。本文阐述了与HER-2阳性乳腺癌预后相关的生物标志物，希望能对临床治疗方案的选择提供参考，提高治疗效率。
Abstract: Human epidermal growth factor receptor-2 (HER-2)-positive breast cancer is a specific type of breast cancer with a poor prognosis. Neoadjuvant chemotherapy combined with targeted therapy, i.e., neoadjuvant therapy, has become an important component in the comprehensive treatment of this type of breast cancer. Pathologic complete remission (pCR) has been recognized as an inde-pendent prognostic predictor for HER-2-positive breast cancer. During neoadjuvant therapy, some patients develop resistance to therapeutic agents, which can affect prognosis. Finding appropriate prognostic predictors and changing the optimal treatment regimen in time can greatly improve the prognosis of HER-2 positive breast cancer patients. This article describes the biomarkers associated with the prognosis of HER-2-positive breast cancer in the hope that they can provide reference for the selection of clinical treatment programs and improve the efficiency of treatment.
文章引用：张立雪, 冯月, 欧江华. 关于HER-2阳性乳腺癌新辅助治疗疗效预测指标的研究进展[J]. 临床医学进展, 2024, 14(3): 374-381. https://doi.org/10.12677/ACM.2024.143712

参考文献

[1] Ferlay, J., Colombet, M., Soerjomataram, I., et al. (2021) Cancer Statistics for the Year 2020: An Overview. Internation-al Journal of Cancer, 149, 778-789. [Google Scholar] [CrossRef] [PubMed]
[2] 杨壹羚, 宋园明, 薛慧琴, 孙卉, 李崖青, 钱晓龙, 焦娇, 李鲲鹏, 张恒, 郭晓静. 人表皮生长因子受体2瘤内异质性乳腺癌的病理学特征和免疫微环境[J]. 中华肿瘤杂志, 2023, 45(2): 165-169.
[3] Tural, D., Akar, E., Mutlu, H., et al. (2014) P95 HER2 Fragments and Breast Cancer Outcome. Expert Review of Anticancer Therapy, 14, 1089-1096. [Google Scholar] [CrossRef] [PubMed]
[4] Slamon, D.J., Clark, G.M., Wong, S.G., et al. (1987) Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/Neu Oncogene. Science, 235, 177-182. [Google Scholar] [CrossRef] [PubMed]
[5] Lipton, A., Goodman, L., Leitzel, K., et al. (2013) HER3, P95HER2, and HER2 Protein Expression Levels Define Multiple Subtypes of HER2-Positive Metastatic Breast Cancer. Breast Cancer Research and Treatment, 141, 43-53. [Google Scholar] [CrossRef] [PubMed]
[6] 程瑞, 纪文鑫, 周灿, 等. HER-2阳性乳腺癌新辅助治疗的热点问题与研究进展[J]. 中国普通外科杂志, 2023, 32(5): 771-781.
[7] 任瑞琴, 刘剑锋. 晚期HER-2阳性乳腺癌的最新治疗策略[J]. 海峡药学, 2023, 35(11): 79-82.
[8] 邵志敏, 吴炅, 江泽飞, 等. 中国乳腺癌新辅助治疗专家共识(2022年版) [J]. 中国癌症杂志, 2022, 32(1): 80-89. [Google Scholar] [CrossRef] 
[9] Zhao, F.X., Huo, X.F., Wang, M.Z., et al. (2021) Comparing Biomarkers for Predicting Pathological Responses to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 11, Article 731148. [Google Scholar] [CrossRef] [PubMed]
[10] Orsaria, P., Grasso, A., Ippolito, E., et al. (2021) Clinical Outcomes among Major Breast Cancer Subtypes after Neoadjuvant Chemotherapy: Impact on Breast Cancer Recurrence and Sur-vival. Anticancer Research, 41, 2697-2709. [Google Scholar] [CrossRef] [PubMed]
[11] Swain, S.M., Tang, G., Lucas, P.C., et al. (2019) Pathologic Com-plete Response and Outcomes by Intrinsic Subtypes in NSABP B-41, a Randomized Neoadjuvant Trial of Chemotherapy with Trastuzumab, Lapatinib, or the Combination. Breast Cancer Research and Treatment, 178, 389-399. [Google Scholar] [CrossRef] [PubMed]
[12] Hamy, A.S., Belin, L., Bonsang-Kitzis, H., et al. (2018) Patho-logical Complete Response and Prognosis after Neoadjuvant Chemotherapy for HER2-Positive Breast Cancers before and after Trastuzumab Era: Results from a Real-Life Cohort. British Journal of Cancer, 118, e14. [Google Scholar] [CrossRef] [PubMed]
[13] Katayama, A., Miligy, I.M., Shiino, S., et al. (2021) Predictors of Patho-logical Complete Response to Neoadjuvant Treatment and Changes to Post-Neoadjuvant HER2 Status in HER2-Positive Invasive Breast Cancer. Modern Pathology, 34, 1271-1281. [Google Scholar] [CrossRef] [PubMed]
[14] 伍雁琦, 罗婷. 激素受体/人表皮生长因子受体2阳性乳腺癌治疗研究进展[J]. 中国全科医学, 2021, 24(8): 1028-1032, 1036.
[15] Lv, H.M., Yan, M. and Jiang, Z.F. (2021) Recent Advances in the Treatment of Hormone Re-ceptor-Positive/Human Epidermal Growth Factor 2-Positive Advanced Breast Cancer. Therapeutic Advances in Medical Oncology, 13. [Google Scholar] [CrossRef] [PubMed]
[16] Shia, W.C., Huang, Y.L., Wu, H.K., et al. (2017) Using Flow Characteristics in Three-Dimensional Power Doppler Ultrasound Imaging to Predict Complete Responses in Patients Undergoing Neoadjuvant Chemotherapy. Journal of Ultrasound in Medicine, 36, 887-900. [Google Scholar] [CrossRef] [PubMed]
[17] Shia, W.C., Chen, D.R., Huang, Y.L., et al. (2015) Effectiveness of Evaluating Tumor Vascularization Using 3D Power Doppler Ultrasound with High-Definition Flow Technology in the Prediction of the Response to Neoadjuvant Chemotherapy for T2 Breast Cancer: A Preliminary Report. Physics in Medi-cine & Biology, 60, 7763-7778. [Google Scholar] [CrossRef] [PubMed]
[18] 陈煌婧, 陈秀华, 何英. 多模态超声和基于超声深度学习的影像组学在预测乳腺癌患者新辅助化疗疗效中的研究进展[J]. 中国临床医学影像杂志, 2023, 34(8): 593-596.
[19] Han, X., Jin, S.Y., Yang, H.J., et al. (2021) Application of Conventional Ultrasonography Combined with Contrast-Enhanced Ultrasonography in the Axillary Lymph Nodes and Evaluation of the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer Patients. British Journal of Radiology, 94, Article ID: 20210520. [Google Scholar] [CrossRef] [PubMed]
[20] Wan, C.F., Liu, X.S., Wang, L., et al. (2018) Quantitative Con-trast-Enhanced Ultrasound Evaluation of Pathological Complete Response in Patients with Locally Advanced Breast Cancer Receiving Neoadjuvant Chemotherapy. European Journal of Radiology, 103, 118-123. [Google Scholar] [CrossRef] [PubMed]
[21] Li, S.P., Makris, A., Beresford, M.J., et al. (2011) Use of Dy-namic Contrast-Enhanced MR Imaging to Predict Survival in Patients with Primary Breast Cancer Undergoing Neoadju-vant Chemotherapy. Radiology, 260, 68-78. [Google Scholar] [CrossRef] [PubMed]
[22] 霍翔, 吴兵, 方德根, 等. HER2阳性乳腺癌新辅助化疗疗效的影响因素及列线图预测模型建立[J]. 川北医学院学报, 2023, 38(1): 126-129, 136.
[23] Dong, J.M., Wang, H.X., Zhong, X.F., et al. (2018) Changes in Background Parenchymal Enhancement in HER2-Positive Breast Cancer before and after Neoadjuvant Chemotherapy: Association with Pathologic Complete Response. Medicine, 97, e12965. [Google Scholar] [CrossRef] 
[24] 燕晶晶, 龙泓, 于晶, 等. FMRI预测乳腺癌新辅助化疗预后的研究进展[J]. 中国中西医结合影像学杂志, 2023, 21(3): 340-343, 350.
[25] Dialani, V., Chadashvili, T. and Slanetz, P.J. (2015) Role of Imaging in Neoadjuvant Therapy for Breast Cancer. Annals of Surgical Oncology, 22, 1416-1424. [Google Scholar] [CrossRef] [PubMed]
[26] Perrier, A., Gligorov, J., Lefèvre, G., et al. (2018) The Extracellular Domain of Her2 in Serum as a Biomarker of Breast Cancer. Laboratory Investigation, 98, 696-707. [Google Scholar] [CrossRef] [PubMed]
[27] 孙佳俊, 卢仁泉, 郑慧, 等. 血清HER2-ECD水平在乳腺癌新辅助化疗中的应用价值分析[J]. 中国癌症杂志, 2019, 29(1): 32-36. [Google Scholar] [CrossRef] 
[28] Wang, T., Zhou, J.M., Zhang, S.H., et al. (2016) Meaningful Interpretation of Serum HER2 ECD Levels Requires Clear Patient Clinical Background, and Serves Several Functions in the Efficient Management of Breast Cancer Patients. Clinica Chimica Acta, 458, 23-29. [Google Scholar] [CrossRef] [PubMed]
[29] Arribas, J., Baselga, J., Pedersen, K., et al. (2011) P95HER2 and Breast Cancer. Cancer Research, 71, 1515-1519. [Google Scholar] [CrossRef] 
[30] Maria, A.M., El-Shebiney, M., El-Saka, A.M., et al. (2018) Expression of Truncated HER2 and Its Prognostic Value in HER2-Positive Breast Cancer Patients. Journal of the Egyp-tian National Cancer Institute, 30, 49-55. [Google Scholar] [CrossRef] [PubMed]
[31] Cai, X., Liu, C., Zhang, T.N., et al. (2018) Down-Regulation of FN1 Inhibits Colorectal Carcinogenesis by Suppressing Proliferation, Migration, and Invasion. Journal of Cellular Bio-chemistry, 119, 4717-4728. [Google Scholar] [CrossRef] [PubMed]
[32] 余楷婷, 王东, 钟豪, 等. 纤维连接蛋白1在乳腺癌中的表达及其与人类表皮生长因子受体2的相关性研究[J]. 中华普通外科学文献(电子版), 2023, 17(3): 203-210.
[33] Denkert, C., Huober, J., Loibl, S., et al. (2013) HER2 and ESR1 MRNA Expression Levels and Response to Neoadjuvant Trastuzumab Plus Chemotherapy in Patients with Primary Breast Cancer. Breast Cancer Researc, 15, Article No. R11. [Google Scholar] [CrossRef] [PubMed]
[34] Wang, X.Y., Bi, X.W., Huang, Z.Z., et al. (2020) The Prognostic Value of Androgen Receptor (AR) in HER2-Enriched Metastatic Breast Cancer. Endocrine-Related Cancer, 27, 199-208. [Google Scholar] [CrossRef] 
[35] Akashi, M., Yamaguchi, R., Kusano, H., et al. (2020) Androgen Re-ceptor Expression Is Useful to Predict the Therapeutic Effect in HER2-Positive Breast Carcinoma. Breast Cancer Re-search and Treatment, 184, 277-285. [Google Scholar] [CrossRef] [PubMed]
[36] Venema, C.M., Bense, R.D., Steenbruggen, T.G., et al. (2019) Consideration of Breast Cancer Subtype in Targeting the Androgen Receptor. Pharmacology & Therapeutics, 200, 135-147. [Google Scholar] [CrossRef] [PubMed]
[37] Li, J.Y., Zhang, S., Ye, C., et al. (2022) Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy. Journal of Personalized Medicine, 12, Article 261. [Google Scholar] [CrossRef] [PubMed]
[38] 琚倩, 史加宁, 杨继鑫, 等. IHC与FISH对HER2阳性乳腺癌新辅助靶向治疗疗效的预测价值[J]. 中华肿瘤防治杂志, 2022, 29(2): 135-140. [Google Scholar] [CrossRef] 
[39] Dieci, M.V., Prat, A., Tagliafico, E., et al. (2016) Integrated Evaluation of PAM50 Subtypes and Immune Modulation of PCR in HER2-Positive Breast Cancer Patients Treated with Chemotherapy and HER2-Targeted Agents in the CherLOB Trial. Annals of Oncology, 27, 1867-1873. [Google Scholar] [CrossRef] [PubMed]
[40] 李娟, 叶斯斯, 白莉. 曲妥珠单抗耐药机制及其逆转策略[J]. 解放军医学院学报, 2017, 38(6): 571-574.
[41] Rothé, F., Silva, M.J., Venet, D., et al. (2019) Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial. Clinical Cancer Research, 25, 3581-3588. [Google Scholar] [CrossRef] 
[42] Ma, F., Li, Q., Chen, S.S., et al. (2017) Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 35, 3105-3112. [Google Scholar] [CrossRef] 
[43] 谢芳, 马骖, 吴玲玲, 等. 肿瘤浸润淋巴细胞在不同分子亚型乳腺癌新辅助化疗中的作用[J]. 实用医学杂志, 2021, 37(17): 2243-2246, 2251.
[44] Liu, S.W., Duan, X.N., Xu, L., et al. (2015) Optimal Threshold for Stromal Tumor-Infiltrating Lymphocytes: Its Predictive and Prognostic Value in HER2-Positive Breast Cancer Treated with Trastuzumab-Based Neoadjuvant Chemotherapy. Breast Cancer Research and Treatment, 154, 239-249. [Google Scholar] [CrossRef] [PubMed]
[45] Nuciforo, P., Pascual, T., Cortés, J., et al. (2018) A Predictive Model of Pathologic Response Based on Tumor Cellularity and Tumor-Infiltrating Lymphocytes (CelTIL) in HER2-Positive Breast Cancer Treated with Chemo-Free Dual HER2 Blockade. Annals of On-cology, 29, 170-177. [Google Scholar] [CrossRef] [PubMed]
[46] Liu, Xi.W., Lu, Y.W., Huang, J.Y., et al. (2022) CD16 Fibroblasts Foster a Trastuzumab-Refractory Microenvironment That Is Reversed by VAV2 Inhibition. Cancer Cell, 40, 1341-1357.E13. [Google Scholar] [CrossRef] [PubMed]
[47] Hou, Y.J., Nitta, H., Wei, L., et al. (2018) PD-L1 Expression and CD8-Positive T Cells Are Associated with Favorable Survival in HER2-Positive Invasive Breast Cancer. The Breast Journal, 24, 911-919. [Google Scholar] [CrossRef] [PubMed]
[48] Di Modica, M., Gargari, G., Regondi, V., et al. (2021) Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer. Cancer Research, 81, 2195-2206. [Google Scholar] [CrossRef] 

为你推荐